Mineralys Therapeutics Inc (MLYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 114,091 | 49,304 | 87,701 | 10,612 | 1,409 |
| Marketable Securities | 84,096 | 187,263 | 22,409 | N/A | N/A |
| TOTAL | $205,351 | $249,103 | $112,811 | $11,122 | $1,466 |
| Non-Current Assets | |||||
| PPE Net | 53 | 0 | N/A | N/A | N/A |
| Investments And Advances | 0 | 2,482 | 0 | 0 | 0 |
| Other Non-Current Assets | 499 | 51 | 1,631 | 3 | 20 |
| TOTAL | $552 | $2,533 | $1,631 | $3 | $20 |
| Total Assets | $205,903 | $251,636 | $114,442 | $11,125 | $1,486 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 479 | 601 | 1,907 | 763 | 529 |
| Accrued Expenses | 14,167 | 9,881 | 6,160 | 4,291 | 54 |
| TOTAL | $14,646 | $10,482 | $8,067 | $5,054 | $5,083 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 158,644 | 28,996 | 0 |
| TOTAL | $N/A | $N/A | $158,644 | $28,996 | $N/A |
| Total Liabilities | $14,646 | $10,482 | $166,711 | $34,050 | $5,083 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 49,836 | 49,631 | 40,857 | N/A | N/A |
| Common Shares | 5 | 4 | 1 | 1 | 1 |
| Retained earnings | -302,518 | -124,708 | -52,810 | -23,011 | -3,603 |
| TOTAL | $191,257 | $241,154 | $-52,269 | $-22,925 | $-3,597 |
| Total Liabilities And Equity | $205,903 | $251,636 | $114,442 | $11,125 | $1,486 |